[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:double-strand-break-repair-protein-mre11":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Double-Strand Break Repair Protein MRE11",5,3,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[20],"Phase 1","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":30,"title":31,"phases":32,"status":33,"updated_at":34,"content_modified":35},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]